Moderna (MRNA) Competitors $33.64 -0.64 (-1.87%) Closing price 04:00 PM EasternExtended Trading$33.57 -0.07 (-0.21%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRNA vs. CRSP, CVAC, HOOD, NVAX, OCGN, TSLA, JNJ, MRK, PFE, and ARGXShould you be buying Moderna stock or one of its competitors? The main competitors of Moderna include CRISPR Therapeutics (CRSP), CureVac (CVAC), Robinhood Markets (HOOD), Novavax (NVAX), Ocugen (OCGN), Tesla (TSLA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), and argenex (ARGX). Moderna vs. Its Competitors CRISPR Therapeutics CureVac Robinhood Markets Novavax Ocugen Tesla Johnson & Johnson Merck & Co., Inc. Pfizer argenex Moderna (NASDAQ:MRNA) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends. Does the media refer more to MRNA or CRSP? In the previous week, Moderna had 12 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 24 mentions for Moderna and 12 mentions for CRISPR Therapeutics. Moderna's average media sentiment score of 0.73 beat CRISPR Therapeutics' score of 0.60 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 11 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, MRNA or CRSP? Moderna has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Is MRNA or CRSP more profitable? Moderna has a net margin of -105.67% compared to CRISPR Therapeutics' net margin of -1,023.64%. CRISPR Therapeutics' return on equity of -20.08% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-105.67% -28.69% -21.94% CRISPR Therapeutics -1,023.64%-20.08%-17.13% Do insiders and institutionals hold more shares of MRNA or CRSP? 75.3% of Moderna shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 11.0% of Moderna shares are owned by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend MRNA or CRSP? Moderna currently has a consensus price target of $46.61, suggesting a potential upside of 38.56%. CRISPR Therapeutics has a consensus price target of $71.75, suggesting a potential upside of 26.32%. Given Moderna's higher probable upside, equities research analysts clearly believe Moderna is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 15 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.53 Which has higher earnings and valuation, MRNA or CRSP? CRISPR Therapeutics has lower revenue, but higher earnings than Moderna. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.24B4.02-$3.56B-$8.73-3.85CRISPR Therapeutics$37.31M131.47-$366.25M-$4.52-12.57 SummaryModerna beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks. Get Moderna News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRNA vs. The Competition Export to ExcelMetricModernaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.26B$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.01%P/E Ratio-3.8520.5827.9620.25Price / Sales4.02292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book1.197.638.045.49Net Income-$3.56B-$55.05M$3.18B$250.27M7 Day Performance10.40%8.54%3.72%4.78%1 Month Performance21.23%5.38%3.72%7.20%1 Year Performance-72.61%2.35%29.92%17.27% Moderna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRNAModerna4.3085 of 5 stars$33.64-1.9%$46.61+38.6%-70.8%$13.26B$3.24B-3.855,800Trending NewsCRSPCRISPR Therapeutics3.227 of 5 stars$50.78-2.7%$71.75+41.3%+6.2%$4.38B$37.31M-11.23460Analyst ForecastOptions VolumeCVACCureVac4.6868 of 5 stars$5.44-0.3%$6.83+25.7%+75.2%$1.22B$579.18M5.91880Positive NewsHOODRobinhood Markets3.304 of 5 stars$92.77-1.7%$69.76-24.8%+342.2%$82.24B$2.95B52.772,300Trending NewsAnalyst ForecastInsider TradeNVAXNovavax4.3467 of 5 stars$6.63-2.6%$17.00+156.6%-40.5%$1.07B$682.16M2.501,990OCGNOcugen1.5225 of 5 stars$0.92-4.0%$6.00+552.9%-36.5%$268.08M$4.05M-4.8380TSLATesla4.7135 of 5 stars$291.99-7.4%$301.60+3.3%+17.7%$1.02T$95.72B160.42125,665Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionJNJJohnson & Johnson4.7708 of 5 stars$155.34-0.4%$170.88+10.0%+5.6%$373.69B$88.82B17.28138,100Trending NewsUpcoming EarningsAnalyst ForecastMRKMerck & Co., Inc.4.9962 of 5 stars$81.22+0.4%$109.19+34.4%-34.0%$203.86B$64.17B11.8275,000Trending NewsAnalyst ForecastAnalyst RevisionPFEPfizer4.97 of 5 stars$25.25-0.5%$28.55+13.1%-9.1%$143.52B$63.63B18.2981,000Trending NewsAnalyst RevisionARGXargenex4.4149 of 5 stars$542.41-0.2%$728.06+34.2%+20.6%$33.10B$2.25B33.441,599Analyst Upgrade Related Companies and Tools Related Companies CRISPR Therapeutics Alternatives CureVac Alternatives Robinhood Markets Alternatives Novavax Alternatives Ocugen Alternatives Tesla Alternatives Johnson & Johnson Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives argenex Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRNA) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moderna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moderna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRNA Stock Alerts